Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ).
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has issued a positive profit alert for its estimated 2024 annual results, indicating a substantial turnaround from losses in the previous year to projected net profits between RMB 589 million and RMB 711 million. The improved operating environment for the heparin industry, coupled with the company’s strategic international expansion and increased sales of enoxaparin sodium products, has bolstered its market position and financial performance.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the production and development of heparin-related products. The company holds a significant presence in the global market, particularly with its finished dose enoxaparin sodium pharmaceutical products, which are marketed in Europe, the United States, China, and other regions.
YTD Price Performance: -4.55%
Average Trading Volume: 747,511
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$14.36B
For an in-depth examination of 9989 stock, go to TipRanks’ Stock Analysis page.
